ReviewFuture oncology (London, England)2026
How I treat soft tissue sarcomas.
Review in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas are mesenchymal malignancies with heterogeneous biological behavior and response to therapy. Surgery remains the gold standard approach for localized disease, with perioperative radiotherapy recommended for high-risk extremity tumors. The benefit of perioperative chemotherapy remains controversial. In the metastatic setting, anthracycline-based chemotherapy has been the first-line treatment for decades. Chemotherapy regimens upon progression to anthracyclines offer very limited disease control. Immune checkpoint inhibitors and T-cell receptor therapies have shown promising clinical activity in some histology subtypes. Advances in molecular profiling have revealed novel actionable targets, and several tailored therapies have proven to be highly effective in tumors harboring specific mutations. This review provides a comprehensive overview of current treatment strategies for soft tissue sarcomas, with emphasis on multidisciplinary management and the importance of developing histology-specific clinical trials to improve outcomes in these rare malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.